These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 29457489)

  • 1. Shingrix: The New Adjuvanted Recombinant Herpes Zoster Vaccine.
    James SF; Chahine EB; Sucher AJ; Hanna C
    Ann Pharmacother; 2018 Jul; 52(7):673-680. PubMed ID: 29457489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Herpes zoster subunit vaccine for the prevention of herpes zoster.
    Symoniak MR; Farrokh P; Gandhi MA; Slish JC
    Am J Health Syst Pharm; 2018 Jun; 75(12):861-869. PubMed ID: 29880523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study.
    Lal H; Poder A; Campora L; Geeraerts B; Oostvogels L; Vanden Abeele C; Heineman TC
    Vaccine; 2018 Jan; 36(1):148-154. PubMed ID: 29174683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.
    Grupping K; Campora L; Douha M; Heineman TC; Klein NP; Lal H; Peterson J; Vastiau I; Oostvogels L
    J Infect Dis; 2017 Dec; 216(11):1343-1351. PubMed ID: 29029122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial.
    Godeaux O; Kovac M; Shu D; Grupping K; Campora L; Douha M; Heineman TC; Lal H
    Hum Vaccin Immunother; 2017 May; 13(5):1051-1058. PubMed ID: 28068212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su.
    Strezova A; Godeaux O; Aggarwal N; Leroux-Roels G; Lopez-Fauqued M; Van Damme P; Vanden Abeele C; Vastiau I; Heineman TC; Lal H
    Vaccine; 2017 Dec; 35(48 Pt B):6700-6706. PubMed ID: 29079101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older.
    Schwarz TF; Aggarwal N; Moeckesch B; Schenkenberger I; Claeys C; Douha M; Godeaux O; Grupping K; Heineman TC; Fauqued ML; Oostvogels L; Van den Steen P; Lal H
    J Infect Dis; 2017 Dec; 216(11):1352-1361. PubMed ID: 29029224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shingrix for Herpes Zoster: A Review.
    Shah RA; Limmer AL; Nwannunu CE; Patel RR; Mui UN; Tyring SK
    Skin Therapy Lett; 2019 Jul; 24(4):5-7. PubMed ID: 31339679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine profile of herpes zoster (HZ/su) subunit vaccine.
    Cunningham AL; Heineman T
    Expert Rev Vaccines; 2017 Jul; 16(7):1-10. PubMed ID: 28486850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.
    Cunningham AL; Lal H; Kovac M; Chlibek R; Hwang SJ; Díez-Domingo J; Godeaux O; Levin MJ; McElhaney JE; Puig-Barberà J; Vanden Abeele C; Vesikari T; Watanabe D; Zahaf T; Ahonen A; Athan E; Barba-Gomez JF; Campora L; de Looze F; Downey HJ; Ghesquiere W; Gorfinkel I; Korhonen T; Leung E; McNeil SA; Oostvogels L; Rombo L; Smetana J; Weckx L; Yeo W; Heineman TC;
    N Engl J Med; 2016 Sep; 375(11):1019-32. PubMed ID: 27626517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the potential public health impact of Herpes Zoster vaccination in Germany.
    Curran D; Van Oorschot D; Varghese L; Oostvogels L; Mrkvan T; Colindres R; von Krempelhuber A; Anastassopoulou A
    Hum Vaccin Immunother; 2017 Oct; 13(10):2213-2221. PubMed ID: 28708959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.
    Lal H; Cunningham AL; Godeaux O; Chlibek R; Diez-Domingo J; Hwang SJ; Levin MJ; McElhaney JE; Poder A; Puig-Barberà J; Vesikari T; Watanabe D; Weckx L; Zahaf T; Heineman TC;
    N Engl J Med; 2015 May; 372(22):2087-96. PubMed ID: 25916341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A critical appraisal of 'Shingrix', a novel herpes zoster subunit vaccine (HZ/Su or GSK1437173A) for varicella zoster virus.
    Bharucha T; Ming D; Breuer J
    Hum Vaccin Immunother; 2017 Aug; 13(8):1789-1797. PubMed ID: 28426274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of an AS01-adjuvanted varicella zoster virus subunit candidate vaccine (HZ/su): a phase-I, open-label study in Japanese adults.
    Lal H; Zahaf T; Heineman TC
    Hum Vaccin Immunother; 2013 Jul; 9(7):1425-9. PubMed ID: 23584252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults.
    Leroux-Roels I; Leroux-Roels G; Clement F; Vandepapelière P; Vassilev V; Ledent E; Heineman TC
    J Infect Dis; 2012 Oct; 206(8):1280-90. PubMed ID: 22872734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, reactogenicity, and safety of the adjuvanted recombinant zoster vaccine for the prevention of herpes zoster in Chinese adults ≥ 50 years: A randomized, placebo-controlled trial.
    Alexandra Echeverria Proano D; Zhu F; Sun X; Zoco J; Soni J; Parmar N; Ali SO;
    Hum Vaccin Immunother; 2024 Dec; 20(1):2351584. PubMed ID: 38838170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccines for preventing herpes zoster in older adults.
    Gagliardi AM; Andriolo BN; Torloni MR; Soares BG
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD008858. PubMed ID: 26937872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Herpes Zoster Vaccines.
    Harbecke R; Cohen JI; Oxman MN
    J Infect Dis; 2021 Sep; 224(12 Suppl 2):S429-S442. PubMed ID: 34590136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials.
    Kovac M; Lal H; Cunningham AL; Levin MJ; Johnson RW; Campora L; Volpi A; Heineman TC;
    Vaccine; 2018 Mar; 36(12):1537-1541. PubMed ID: 29463421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of a Herpes Zoster subunit vaccine in Japanese population aged ≥50 years when administered subcutaneously vs. intramuscularly.
    Vink P; Shiramoto M; Ogawa M; Eda M; Douha M; Heineman T; Lal H
    Hum Vaccin Immunother; 2017 Mar; 13(3):574-578. PubMed ID: 27936344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.